Content about Biovail Labs International

February 8, 2011

Valeant Pharmaceuticals subsidiary Biovail Labs International has licensed Canadian rights to a treatment for acne from Allergan, Valeant said Tuesday.

MISSISSAUGA, Ontario — Valeant Pharmaceuticals subsidiary Biovail Labs International has licensed Canadian rights to a treatment for acne from Allergan, Valeant said Tuesday.

Under the terms of the agreement concerning the drug Aczone (dapsone) gel in the 5% strength, Biovail will pay Allergan about $500,000 Canadian dollars (about $504,693) upfront, as well as payments based on net sales.